Tocilizumab monotherapy in a patient with rheumatoid arthritis and iatrogenic Kaposi sarcoma

Francesca Ingegnoli, Athanasia Tourlaki, Roberta Gualtierotti

Research output: Contribution to journalArticle

Abstract

Kaposi sarcoma (KS) is a human herpesvirus-8-associated lymphoangioproliferative neoplasm. Both human and viral interleukin-6 (IL-6) proteins seem to drive much of the clinical manifestations of KS, which provides a new target for intervention by using IL-6-neutralizing antibodies. We describe the clinical course of a patient in whom tocilizumab, a monoclonal anti-IL-6 receptor antibody approved for rheumatoid arthritis (RA) treatment, was effective not only in inducing RA remission but was also safe for KS.

Original languageEnglish
Pages (from-to)159-161
Number of pages3
JournalClinical Drug Investigation
Volume34
Issue number2
DOIs
Publication statusPublished - 2014

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Tocilizumab monotherapy in a patient with rheumatoid arthritis and iatrogenic Kaposi sarcoma'. Together they form a unique fingerprint.

  • Cite this